Cellebrite DI Ltd. SEC filings document its foreign private issuer reporting for an AI-powered digital investigative and intelligence software business. Form 6-K current reports furnish quarterly and annual results releases, GAAP financial tables incorporated by reference into Form S-8 and Form F-3 registration statements, and annual general meeting voting results under the Israeli Companies Law and the company’s articles of association.
The filing record also includes Form 20-F annual reporting, which provides the recurring public-company framework for Cellebrite’s business, financial reporting and ordinary-share governance disclosures.
CLBT-related Form 144 filing reports planned resale and recent brokered sales of company common stock. The filing lists 3,064 Restricted Stock Units noted for sale on 05/20/2026. It also records recent 10b5-1 dispositions by David Gee: 228 shares on 05/12/2026, 2,609 shares on 02/23/2026, and 4,517 shares on 02/24/2026 with dollar amounts shown alongside each trade.
Cellebrite DI Ltd. submitted a Form 144 reporting proposed sales of Ordinary Shares by an insider. The form lists 5,673 Restricted Share Units vested under an S-8 plan (05/20/2026) and shows recent sales by David Gee: 2,609 shares on 02/23/2026, 4,517 shares on 02/24/2026 and 228 shares on 05/12/2026. The filing describes these transactions as employee compensation and restricted‑unit vesting.
Cellebrite DI Ltd. Global Chief Revenue Officer Marcus Jewell reported an open-market sale of 12,658 ordinary shares at a weighted average price of $12.7711 per share. The shares were originally granted as RSUs, and the disposition is associated with tax obligations from their vesting. Following the sale, Jewell directly holds 440,101 ordinary shares.
Cellebrite DI Ltd. submitted a Form 144 notice regarding proposed sales of Ordinary shares arising from vested restricted share units. The filing shows 31,728 Ordinary shares vested under an S-8 registered plan on 05/15/2026. The filing also reports recent sales by Marcus Jewell of 4,613 shares on 02/18/2026 for $65,221.36 and 383 shares on 05/12/2026 for $4,983.33.
Cellebrite DI Ltd. Chief Marketing Officer David Nicholas Gee reported a small open-market sale of company shares linked to tax obligations from vested equity awards. He sold 228 ordinary shares at a weighted average price of $13.01 per share, with individual trades ranging from $12.84 to $13.175. These shares originated from restricted stock units granted on February 11, 2025 and were sold to cover associated tax liabilities. After the transaction, Gee directly owned 147,705 ordinary shares, indicating that the sale represented only a minor portion of his overall holdings.
Cellebrite DI Ltd. Global Chief Revenue Officer Marcus Jewell reported an open-market sale of 383 ordinary shares at a weighted average price of $13.01 per share. The footnotes explain the disposition is associated with tax obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Jewell directly holds 452,759 ordinary shares.
Ramji Shiven reported acquisition or exercise transactions in this Form 4 filing.
Cellebrite DI Ltd. reported that President Products & Tech Ramji Shiven received a compensation grant of 423,550 restricted share units (RSUs), each representing one ordinary share when settled. Following this award, he holds 423,550 ordinary shares directly.
The RSUs vest over time: 105,898 vest on May 4, 2027, and 26,471 additional RSUs vest every three months through May 4, 2030, encouraging long-term retention and performance alignment.
Cellebrite DI Ltd. reported strong growth for the first quarter of 2026. Revenue rose to $128.3 million from $107.5 million, driven mainly by subscription services, which increased to $96.5 million. GAAP net income declined to $10.9 million from $17.4 million as operating expenses rose.
On a non-GAAP basis, operating income improved to $28.6 million and adjusted EBITDA increased to $30.6 million, with an adjusted EBITDA margin of 23.9%. The company highlighted annual recurring revenue growth of 21% and a trailing 12‑month free cash flow margin of 32%, reflecting a cash‑generative subscription model.
For the second quarter of 2026, Cellebrite expects ARR of $510–$513 million and revenue of $130–$133 million, with adjusted EBITDA of $29–$31 million. Full‑year 2026 guidance calls for ARR of $567–$573 million, revenue of $565–$571 million, and adjusted EBITDA of $149–$155 million, implying healthy profitability and continued growth.
Cellebrite DI Ltd. filed a Form 144 reporting a proposed resale of 1,045 ordinary shares as vested Restricted Share Units under an S-8 registered plan on 05/11/2026. The filing also lists recent open-market sales by Marcus Jewell of 1,779, 13,276, and 4,613 ordinary shares with trade dates in 02/2026.
Cellebrite DI Ltd. submitted a Form 144 notice reporting proposed sales of ordinary shares and related transactions. The filing lists 653 Restricted Share Units vested under an issuer S-8 registered plan on 05/11/2026 and shows recent sales by an affiliate, David Gee, of 1,165, 2,609, and 4,517 ordinary shares on 02/12/2026, 02/23/2026, and 02/24/2026, respectively.